title: Children's Oncology Group's 2013 blueprint for research: bone tumors.
abstract: In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.
authors.affiliation: The Department of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10467, USA. rgorlick@montefiore.org
authors.forename: Richard
authors.initials: R
authors.lastname: Gorlick
authors.forename: Katherine
authors.initials: K
authors.lastname: Janeway
authors.forename: Stephen
authors.initials: S
authors.lastname: Lessnick
authors.forename: R Lor
authors.initials: RL
authors.lastname: Randall
authors.forename: Neyssa
authors.initials: N
authors.lastname: Marina
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy*; D012106:Research; D012512:Sarcoma, Ewing / Q000188:drug therapy*